High throughput sequencing identifies MicroRNAs mediating α-synuclein toxicity by targeting neuroactive-ligand receptor interaction pathway in early stage of Drosophila Parkinson's disease model

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Kong, Yan ^a   Liang, Xijun ^b   Liu, Lin ^b   Zhang, Dongdong ^c   Wan, Chao ^c   Gan, Zhenji ^b   Yuan, Liudi ^a,c   Jiang, Bing Hua ^d  

^a MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

^b NANJING UNIVERSITY   (China)

^c SOUTHEAST UNIVERSITY   (China)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR BETA3; 4 AMINOBUTYRIC ACID RECEPTOR; ALPHA SYNUCLEIN; DOPAMINE 2 RECEPTOR; MICRORNA; MICRORNA 1008 5P; MICRORNA 133 3P; MICRORNA 137 3P; MICRORNA 13B; MICRORNA 13B 3P; MICRORNA 932 5P; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; NEUROACTIVE LIGAND RECEPTOR; RECEPTOR; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; MESSENGER RNA; NEUROTRANSMITTER RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DROSOPHILA; FEMALE; GENE EXPRESSION REGULATION; GENE SEQUENCE; GENE TARGETING; GENETIC DAMAGE; GENETIC IDENTIFICATION; HIGH THROUGHPUT SEQUENCING; IN VIVO STUDY; MALE; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PROTEIN INTERACTION; 3' UNTRANSLATED REGION; ANIMAL; BIOLOGY; GENE EXPRESSION PROFILING; GENETICS; LOCOMOTION; METABOLISM; MOLECULAR GENETICS; REPRODUCIBILITY; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

3' UNTRANSLATED REGIONS; ALPHA-SYNUCLEIN; ANIMALS; COMPUTATIONAL BIOLOGY; DISEASE MODELS, ANIMAL; DROSOPHILA; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; LOCOMOTION; MALE; MICRORNAS; MOLECULAR SEQUENCE ANNOTATION; PARKINSON DISEASE; RECEPTORS, NEUROTRANSMITTER; REPRODUCIBILITY OF RESULTS; RNA INTERFERENCE; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84945248178     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0137432     Document Type: Article

References (96)

1. Mayeux R. Epidemiology of neurodegeneration. Ann Rev Neurosci. 2003; 26:81-104. PMID: 12574495
2. Spillantini MG, Schmidt ML, Lee V.M., Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997; 388:839-840. PMID: 9278044
3. Chartier-Harlin M.C., Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet. 2004; 364:1167-1169. PMID: 15451224
4. Conway KA, Harper JD, Lansbury PT Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med. 1998; 4:1318-1320. PMID: 9809558
5. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E., Ros R, Ampuero I, et al The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol. 2004; 55:164-173. PMID: 14755719
6. Tenreiro S, Reimao-Pinto MM, Antas P, Rino J, Wawrzycka D, Macedo D, et al. Phosphorylation modulates clearance of alpha-synuclein inclusions in a yeast model of Parkinson's disease. PLoS Genet. 2014; 10:e1004302. doi: 10.1371/journal.pgen.1004302 PMID: 24810576
7. Wang S, Zhang S, Liou L.C., Ren Q., Zhang Z, Caldwell GA, et al Phosphatidylethanolamine deficiency disrupts alpha-synuclein homeostasis in yeast and worm models of Parkinson disease. Proc Natl Acad Sci USA. 2014; 111: E3976-3985. doi: 10.1073/pnas.1411694111 PMID: 25201965
8. Feany MB, Bender WW A Drosophila model of Parkinson's disease. Nature. 2000; 404:394-398. PMID: 10746727
9. Van der Perren A, Macchi F, Toelen J, Carlon MS, Maris M, de Loor H, et al. FK506 reduces neuroinflammation and dopaminergic neurodegeneration in an alpha-synuclein-based rat model for Parkinson's disease. Neurobiol Aging. 2015; 36:1559-1568. doi: 10.1016/j.neurobiolaging.2015.01.014 PMID: 25660193
10. Chen L, Xie Z, Turkson S., Zhuang X. A53T human alpha-synuclein overexpression in transgenic mice induces pervasive mitochondria macroautophagy defects preceding dopamine neuron degeneration. J Neurosci. 2015; 35:890-905. doi: 10.1523/JNEUROSCI.0089-14.2015 PMID: 25609609
11. Barkholt P, Sanchez-Guajardo V, Kirik D, Romero-Ramos M. Long-term polarization of microglia upon alpha-synuclein overexpression in nonhuman primates. Neuroscience. 2012; 208:85-96. doi: 10. 1016/j.neuroscience.2012.02.004 PMID: 22342967
12. Bouleau S, Tricoire H. Drosophila models of Alzheimer's disease: advances, limits, and perspectives. J Alzheimers Dis. 2015; 45:1015-1038. doi: 10.3233/JAD-142802 PMID: 25697708
13. Maheshwari M, Bhutani S, Das A., Mukherjee R, Sharma A, Kino Y, et al. Dexamethasone induces heat shock response and slows down disease progression in mouse and fly models of Huntington's disease. Hum Mol Genet. 2014; 23:2737-2751. doi: 10.1093/hmg/ddt667 PMID: 24381308
14. Chen L, Feany MB Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci. 2005; 8:657-663. PMID: 15834418
15. Periquet M, Fulga T, Myllykangas L, Schlossmacher MG, Feany MB. Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo. J Neurosci. 2007; 27:3338-3346. PMID: 17376994
16. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011; 12:861-874. doi: 10.1038/nrg3074 PMID: 22094949
17. Dorval V, Mandemakers W, Jolivette F., Coudert L, Mazroui R, De Strooper B, et al. Gene and Micro-RNA transcriptome analysis of Parkinson's related LRRK2 mouse models. PloSOne. 2014; 9:e85510. doi: 10.1371/journal.pone.0085510 PMID: 24427314
18. Cardo LF, Coto E, de Mena L, Ribacoba R, Moris G., Menendez M, et al. Profile of microRNAs in the plasma of Parkinson's disease patients and healthy controls. J Neurol. 2013; 260:1420-1422. doi: 10. 1007/s00415-013-6900-8 PMID: 23543376
19. Minones-Moyano E., Porta S, Escaramis G, Rabionet R, Iraola S, Kagerbauer B, et al. MicroRNAprofiling of Parkinson's disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function. Hum Mol Genet. 2011; 20:3067-3068. doi: 10.1093/hmg/ddr210 PMID: 21558425
20. Margis R, Margis R, Rieder CR. Identification of blood microRNAs associated to Parkinsonis disease. J Biotechnol. 2011; 152:96-101. doi: 10.1016/j.jbiotec.2011.01.023 PMID: 21295623
21. Vlachos IS, Kostoulas N, Vergoulis T., Georgakilas G, Reczko M, Maragkakis M., et al. DIANA miRPath v.2.0: investigating the combinatorial effect of microRNAs in pathways. Nucleic Acids Res. 2012; 40 (Web Server issue):W498-504. doi: 10.1093/nar/gks494 PMID: 22649059
22. Huang A, Martin ER, Vance J.M., Cai X. Detecting genetic interactions in pathway-based genome-wide association studies. Genetic Epidemiol. 2014; 38:300-309.
23. Strazisar M, Cammaerts S, van der Ven K, Forero DA, Lenaerts AS, Nordin A, et al. MIR137 variants identified in psychiatric patients affect synaptogenesis and neuronal transmission gene sets. Mol Psychiatry. 2015; 20:472-481. doi: 10.1038/mp.2014.53 PMID: 24888363
24. Zhao L, Li H, Guo R., Ma T, Hou R, Ma X, et al. miR-137, a new target for post-stroke depression? Neural Regen Res. 2013; 8:2441-2448. doi: 10.3969/j.issn.1673-5374.2013.26.005 PMID: 25206554
25. Buttner S, Habernig L, Broeskamp F., Ruli D, Vogtle FN, Vlachos M, et al Endonuclease G mediates alpha-synuclein cytotoxicity during Parkinson's disease. EMBO J. 2013; 32:3041-3054. doi: 10.1038/emboj.2013.228 PMID: 24129513
26. Outeiro TF, Kontopoulos E, Altmann SM, Kufareva I, Strathearn KE, Amore AM, et al. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science 2007; 317:516-519. PMID: 17588900
27. Miura E, Hasegawa T, Konno M, Suzuki M, Sugeno N, Fujikake N, et al. VPS35dysfunction impairs lysosomal degradation of alpha-synuclein and exacerbates neurotoxicity in a Drosophila model of Parkinson's disease. Neurobiol Dis. 2014; 71:1-13. doi: 10.1016/j.nbd.2014.07.014 PMID: 25107340
28. Yin G, Lopes da Fonseca T, Eisbach SE, Anduaga AM, Breda C, Orcellet ML, et al. alpha-Synuclein interacts with the switch region of Rab8a in a Ser129 phosphorylation-dependent manner. Neurobiol Disease 2014; 70:149-161.
29. Butler EK, Voigt A, Lutz A.K., Toegel JP, Gerhardt E, Karsten P, et al The mitochondrial chaperone protein TRAP1 mitigates alpha-Synuclein toxicity. PLoS Genet. 2012; 8:e1002488. doi: 10.1371/journal. pgen.1002488 PMID: 22319455
30. Barone MC, Sykiotis GP, Bohmann D. Genetic activation of Nrf2 signaling is sufficient to ameliorate neurodegenerative phenotypes in a Drosophila model of Parkinson's disease. Dis Model Mech. 2011; 4:701-707. doi: 10.1242/dmm.007575 PMID: 21719443
31. Winslow AR, Chen CW, Corrochano S, Acevedo-Arozena A, Gordon DE, Peden AA, et al. alpha-Synuclein impairs macroautophagy: implications for Parkinson's disease. J Cell Biol. 2010; 190:1023-1037. doi: 10.1083/jcb.201003122 PMID: 20855506
32. Du G, Liu X, Chen X., Song M, Yan Y, Jiao R., et al. Drosophila histone deacetylase 6 protects dopaminergic neurons against {alpha}-synuclein toxicity by promoting inclusion formation. Mol Biol Cell. 2010; 21:2128-2137. doi: 10.1091/mbc.E10-03-0200 PMID: 20444973
33. Todd AM, Staveley BE Pink1 suppresses alpha-synuclein-induced phenotypes in a Drosophila model of Parkinson's disease. Genome. 2008; 51:1040-1046. doi: 10.1139/G08-085 PMID: 19088817
34. Botella JA, Bayersdorfer F, Schneuwly S. Superoxide dismutase overexpression protects dopaminergic neurons in a Drosophila model of Parkinson's disease. Neurobiol Dis. 2008; 30:65-73. doi: 10. 1016/j.nbd.2007.11.013 PMID: 18243716
35. Wassef R, Haenold R, Hansel A., Brot N, Heinemann SH, Hoshi T. Methionine sulfoxide reductase A and a dietary supplement S-methyl-L-cysteine prevent Parkinson's-like symptoms. J Neurosci. 2007; 27:12808-12816. PMID: 18032652
36. Haywood AF, Staveley BE Parkin counteracts symptoms in a Drosophila model of Parkinson's disease. BMC Neurosci. 2004; 5:14. PMID: 15090075
37. Auluck PK, Chan HY, Trojanowski J.Q., Lee VM, Bonini NM. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science. 2002; 295:865-868. PMID: 11823645
38. Pendleton RG, Parvez F, Sayed M., Hillman R. Effects of pharmacological agents upon a transgenic model of Parkinson's disease in Drosophila melanogaster. J Pharmacol ExpTher. 2002; 300:91-96. PMID: 11752102
39. Buttner S, Broeskamp F, Sommer C, Markaki M, Habernig L, Alavian-Ghavanini A, et al. Spermidine protects against alpha-synuclein neurotoxicity. Cell cycle. 2014; 13:3903-3908. doi: 10.4161/15384101.2014.973309 PMID: 25483063
40. Hillman R, Sinani J, Pendleton R. The role of the GABA(B) receptor and calcium channels in a Drosophila model of Parkinson's Disease. Neurosci Lett. 2012; 516:167-170. doi: 10.1016/j.neulet.2012. 03.034 PMID: 22480689
41. Khan S, Jyoti S, Naz F., Shakya B, Rahul, Afzal M, et al. Effect of L-ascorbic Acid on the climbing ability and protein levels in the brain of Drosophila model of Parkinson's disease. Int J Neurosci. 2012; 122:704-709. doi: 10.3109/00207454.2012.709893 PMID: 22776006
42. Siddique YH, Ara G, Jyoti S., Afzal M. The dietary supplementation of nordihydroguaiaretic acid (NDGA) delayed the loss of climbing ability in Drosophila model of Parkinson's disease. J Diet Suppl. 2012; 9:1-8. doi: 10.3109/19390211.2011.630716 PMID: 22432798
43. Shaltiel-Karyo R., Davidi D, Frenkel-Pinter M, Ovadia M., Segal D, Gazit E. Differential inhibition of alpha-synuclein oligomeric and fibrillar assembly in Parkinson's disease model by cinnamon extract. Biochim Biophys Acta. 2012; 1820:1628-1635. doi: 10.1016/j.bbagen.2012.04.021 PMID: 22575665
44. Auluck PK, Meulener MC, Bonini NM Mechanisms of Suppression of {alpha}-Synuclein Neurotoxicity by Geldanamycin in Drosophila. J Biol Chem. 2005; 280:2873-2878. PMID: 15556931
45. Lu JH, Tan JQ, Durairajan S.S., Liu LF, Zhang ZH, Ma L, et al Isorhynchophylline, a natural alkaloid, promotes the degradation of alpha-synuclein in neuronal cells via inducing autophagy. Autophagy. 2012; 8:98-108. doi: 10.4161/auto.8.1.18313 PMID: 22113202
46. Siddique YH, Naz F, Jyoti S. Effect of curcumin on lifespan, activity pattern, oxidative stress, and apoptosis in the brains of transgenic Drosophila model of Parkinson's disease. Biomed Res Int. 2014; 2014:606928. doi: 10.1155/2014/606928 PMID: 24860828
47. Siddique YH, Jyoti S, Naz F. Effect of epicatechin gallate dietary supplementation on transgenic Drosophila model of Parkinson's disease. J Diet Suppl. 2014; 11:121-130. doi: 10.3109/19390211.2013. 859207 PMID: 24670116
48. Shaltiel-Karyo R., Frenkel-Pinter M, Rockenstein E., Patrick C, Levy-Sakin M, Schiller A, et al. Abloodbrain barrier (BBB) disrupter is also a potent alpha-synuclein (alpha-syn) aggregation inhibitor: a novel dual mechanism of mannitol for the treatment of Parkinson disease (PD). J Biol Chem. 2013; 288:17579-17588. doi: 10.1074/jbc.M112.434787 PMID: 23637226
49. St Laurent R., O'Brien LM, Ahmad ST Sodium butyrate improves locomotor impairment and early mortality in a rotenone-induced Drosophila model of Parkinson's disease. Neuroscience. 2013; 246:382-390. doi: 10.1016/j.neuroscience.2013.04.037 PMID: 23623990
50. Siddique YH, Faisal M, Naz F., Jyoti S, Rahul. Roleof Ocimum sanctum leaf extract on dietary supplementation in the transgenic Drosophila model of Parkinson's disease. Chin J Nat Med. 2014; 12:777-781. doi: 10.1016/S1875-5364(14)60118-7 PMID: 25443371
51. Siddique YH, Mujtaba SF, Jyoti S, Naz F. GC-MS analysis of Eucalyptus citriodora leaf extract and its role on the dietary supplementation in transgenic Drosophila model of Parkinson's disease. Food Chem Toxicol. 2013; 55:29-35. doi: 10.1016/j.fct.2012.12.028 PMID: 23318758
52. Long J, Gao H, Sun L., Liu J, Zhao-Wilson X. Grape extract protects mitochondria from oxidative damage and improves locomotor dysfunction and extends lifespan in a Drosophila Parkinson's disease model. Rejuvenation Res. 2009, 12:321-331. doi: 10.1089/rej.2009.0877 PMID: 19929256
53. Kabaria S, Choi DC, Chaudhuri A.D., Mouradian MM, Junn E. Inhibition of miR-34b and miR-34c enhances alpha-synuclein expression in Parkinson's disease. FEBS Lett. 2015; 589:319-325. doi: 10. 1016/j.febslet.2014.12.014 PMID: 25541488
54. Doxakis E. Post-transcriptional regulation of alpha-synuclein expression by mir-7 and mir-153. J Biol Chem. 2010; 285:12726-12734. doi: 10.1074/jbc.M109.086827 PMID: 20106983
55. Kim J, Inoue K, Ishii J., Vanti WB, Voronov SV, Murchison E, et al A MicroRNA feedback circuit in midbrain dopamine neurons. Science. 2007; 317:1220-1224. PMID: 17761882
56. Decressac M, Mattsson B, Weikop P., Lundblad M, Jakobsson J, Bjorklund A. TFEB-mediated autophagy rescues midbrain dopamine neurons from alpha-synuclein toxicity. Proc Natl Acad Sci USA. 2013; 110: E1817-1826. doi: 10.1073/pnas.1305623110 PMID: 23610405
57. Ibanez-Ventoso C., Vora M, Driscoll M. Sequence relationships among C. elegans, D. melanogaster and human microRNAs highlight the extensive conservation of microRNAs in biology. PloS One. 2008; 3:e2818. doi: 10.1371/journal.pone.0002818 PMID: 18665242
58. Jeon YJ, Kim OJ, Kim S.Y., Oh SH, Oh D, Kim OJ, et al Association of the miR-146a, miR-149, miR-196a2, andmiR-499 polymorphisms with ischemic stroke and silent brain infarction risk. Arterioscler thromb Vasc Biol. 2013; 33:420-430. doi: 10.1161/ATVBAHA.112.300251 PMID: 23202363
59. Kong Y, Wu J, Yuan L. MicroRNA expression analysis of adult-onset Drosophila Alzheimer's disease model. Curr Alzheimer Res. 2014; 11:882-891. PMID: 25274109
60. Xin H, Li Y, Buller B., Katakowski M, Zhang Y, Wang X., et al. Exosome-mediated transfer of miR-133b from multipotent mesenchymal stromal cells to neural cells contributes to neurite outgrowth. Stem Cells. 2012; 30:1556-1564. doi: 10.1002/stem.1129 PMID: 22605481
61. Sanchez-Simon F.M., Zhang XX, Loh H.H., Law PY, Rodriguez RE. Morphine regulates dopaminergic neuron differentiation via miR-133b. Mol Pharmacol. 2010; 78:935-942. doi: 10.1124/mol.110.066837 PMID: 20716624
62. Yu YM, Gibbs KM, Davila J, Campbell N., Sung S, Todorova TI, et al. MicroRNA miR-133b is essential for functional recovery after spinal cord injury in adult zebrafish. Eur J Neurosci. 2011; 33:1587-1597. doi: 10.1111/j.1460-9568.2011.07643.x PMID: 21447094
63. Sun G, Ye P, Murai K., Lang MF, Li S, Zhang H, et al miR-137 forms a regulatory loop with nuclear receptor TLX and LSD1 in neural stem cells. Nature Commun. 2011; 2:529.
64. Smrt RD, Szulwach KE, Pfeiffer R.L., Li X., Guo W, Pathania M, et al. MicroRNA miR-137 regulates neuronal maturation by targeting ubiquitin ligase mind bomb-1. Stem Cells. 2010; 28:1060-1070. doi: 10. 1002/stem.431 PMID: 20506192
65. Verma P, Augustine GJ, Ammar MR, Tashiro A, Cohen SM. A neuroprotective role for microRNAmiR-1000 mediated by limiting glutamate excitotoxicity. Nature Neurosci. 2015; 18:379-385. doi: 10.1038/nn.3935 PMID: 25643297
66. Willemsen MH, Valles A, Kirkels L.A., Mastebroek M, Olde Loohuis N, Kos A, et al. Chromosome 1p21.3 microdeletions comprising DPYDand MIR137 are associated with intellectual disability. J Med Genet. 2011; 48:810-818. doi: 10.1136/jmedgenet-2011-100294 PMID: 22003227
67. Wright C, Turner JA, Calhoun V.D., Perrone-Bizzozero N. Potential Impact of miR-137 and Its Targets in Schizophrenia. Front Genet. 2013; 4:58. doi: 10.3389/fgene.2013.00058 PMID: 23637704
68. Yin J, Lin J, Luo X, Chen Y, Li Z, Ma G, Li K. miR-137: a new player in schizophrenia. Int J Mol Sci. 2014; 15:3262-3271. doi: 10.3390/ijms15023262 PMID: 24566148
69. Nalls MA, Saad M, Noyce A.J., Keller MF, Schrag A, Bestwick JP, et al Genetic comorbidities in Parkinson's disease. Hum Mol Genet. 2014; 23:831-841. doi: 10.1093/hmg/ddt465 PMID: 24057672
70. Valles A, Martens GJ, De Weerd P, Poelmans G, Aschrafi A. MicroRNA-137 regulates a glucocorticoid receptor-dependent signalling network: implications for the etiology of schizophrenia. J Psychiatry Neurosci. 2014; 39:312-320. PMID: 24866554
71. Geekiyanage H, Chan C. MicroRNA-137/181c regulates serine palmitoyltransferase and in turn amyloid beta, novel targets in sporadic Alzheimer's disease. J Neurosci. 2011; 31:14820-14830. doi: 10. 1523/JNEUROSCI.3883-11.2011 PMID: 21994399
72. Gao S, Duan C, Gao G., Wang X, Yang H. Alpha-synuclein overexpression negatively regulates insulin receptor substrate 1 by activating mTORC1/S6K1 signaling. Int J BiochemCell Biol. 2015; 64:25-33. doi: 10.1016/j.biocel.2015.03.006 PMID: 25813876
73. Musgrove RE, King AE, Dickson TC a-Synuclein protects neurons from apoptosis downstream of free-radical production through modulation of the MAPK signalling pathway. Neurotox Res. 2013; 23 (4):358-369. doi: 10.1007/s12640-012-9352-5 PMID: 22936601
74. Desplats P, Spencer B, Crews L, Pathel P, Morvinski-Friedmann D, Kosberg K, et al. a-Synuclein induces alterations in adult neurogenesis in Parkinson disease models via p53-mediated repression of Notch1. J Biol Chem. 2012; 287:31691-31702. doi: 10.1074/jbc.M112.354522 PMID: 22833673
75. Golpich M, Amini E, Hemmati F., Ibrahim NM, Rahmani B, Mohamed Z, et al Glycogen synthase kinase-3 beta (GSK-3β) signaling: Implications for Parkinson's disease. Pharmacol Res. 2015; 97:16-26. doi: 10.1016/j.phrs.2015.03.010 PMID: 25829335
76. Jin H, Kanthasamy A, Ghosh A, Yang Y, Anantharam V, Kanthasamy AG. a-Synuclein negatively regulates protein kinase Co expression to suppress apoptosis in dopaminergic neurons by reducing p300 histone acetyltransferase activity. J Neurosci. 2011; 31:2035-2051. doi: 10.1523/JNEUROSCI.5634-10.2011 PMID: 21307242
77. Wu N, Joshi PR, Cepeda C, Masliah E., Levine MS. Alpha-synuclein overexpression in mice alters synaptic communication in the corticostriatal pathway. J Neurosci Res. 2010; 88:1764-1776. doi: 10. 1002/jnr.22327 PMID: 20029978
78. Lee FK, Wong AK, Lee Y.W., Wan OW, Chan HY, Chung KK. The role of ubiquitin linkages on alpha-synuclein induced-toxicity in a Drosophila model of Parkinson's disease. 2009; J Neurochem. 110:208-219. doi: 10.1111/j.1471-4159.2009.06124.x PMID: 19457126
79. Decressac M, Mattsson B, Weikop P., Lundblad M, Jakobsson J, Björklund A. TFEB-mediated autophagy rescues midbrain dopamine neurons from osynuclein toxicity. Proc Natl Acad Sci USA. 2013; 110: E1817-E1826. doi: 10.1073/pnas.1305623110 PMID: 23610405
80. Barone MC, Sykiotis GP, Bohmann D. Genetic activation of Nrf2 signaling is sufficient to ameliorate neurodegenerative phenotypes in a Drosophila model of Parkinson's disease. Dis Model Mech. 2011; 4:701-707. doi: 10.1242/dmm.007575 PMID: 21719443
81. Luo J, Sun L, Lin X., Liu G, Yu J, Parisiadou L., et al. Acalcineurin-and NFAT-dependent pathway is involved in osynuclein-induced degeneration of midbrain dopaminergic neurons. Hum Mol Genet. 2014; 23:6567-74. doi: 10.1093/hmg/ddu377 PMID: 25051958
82. Ryan SD, Dolatabadi N, Chan S.F., Zhang X., Akhtar MW, Parker J, et al. Isogenic human iPSC Parkinson's model shows nitrosative stress-induced dysfunction in MEF2-PGC1 a transcription. Cell. 2013; 155:1351-1364. doi: 10.1016/j.cell.2013.11.009 PMID: 24290359
83. Price DL, Rockenstein E, Ubhi K., Phung V, MacLean-Lewis N, Askay D, et al Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of alpha-synucleinopathy - implications for excitotoxicity. PLoSOne. 2010; 5:e14020. doi: 10.1371/journal.pone.0014020 PMID: 21103359
84. Aoki R, Li YR osynuclein promotes neuroprotection through NF-KB-mediated transcriptional regulation of protein kinase Co. Sci Signal. 2011; 4:jc6. doi: 10.1126/scisignal.2002425 PMID: 22009151
85. Devine MJ. Proteasomal inhibition as a treatment strategy for Parkinson's disease: the impact of o synucleinon Nurr1. J Neurosci. 2012; 32:16071-16073. doi: 10.1523/JNEUROSCI.4224-12.2012 PMID: 23152591
86. Gispert S, Kurz A, Brehm N, Rau K, Walter M, Riess O, Auburger G. Complexin-1 and Foxp1 Expression Changes Are Novel Brain Effects of Alpha-Synuclein Pathology. Mol Neurobiol. 2015; 52:57-63. doi: 10.1007/s12035-014-8844-0 PMID: 25112678
87. Decressac M1, Kadkhodaei B, Mattsson B, Laguna A, Perlmann T, Björklund A. oSynuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons. Sci Transl Med. 2012; 4:163ra156. doi: 10.1126/scitranslmed.3004676 PMID: 23220632
88. Kohno R, Sawada H, Kawamoto Y., Uemura K, Shibasaki H, Shimohama S. BDNF is induced by wildtype alpha-synuclein but not by the two mutants, A30P or A53T, in glioma cell line. Biochem Biophys Res Commun. 2004; 318:113-118. PMID: 15110760
89. Wang B, Liu Q, Shan H, Xia C, Liu Z. Nrf2 inducer and cncC overexpression attenuates neurodegeneration due to osynuclein in Drosophila. Biochem Cell Biol. 2015; 93:351-358. doi: 10.1139/bcb-2015-0015 PMID: 26008822
90. Liu S, Fa M, Ninan I, Trinchese F, Dauer W, Arancio O. Alpha-synuclein involvement in hippocampal synaptic plasticity: role of NO, cGMP, cGKand CaMKII. Eur J Neurosci. 2007; 25:3583-3596. PMID: 17610578
91. Czapski GA, G ssowskaM, Wilkaniec A, Cielik M, Adamczyk A. Extracellular alpha-synuclein induces calpain-dependentoveractivation of cyclin-dependent kinase 5 in vitro. FEBS Lett. 2013; 587:3135-3141. doi: 10.1016/j.febslet.2013.07.053 PMID: 23954626
92. Dulovic M, Jovanovic M, Xilouri M., Stefanis L, Harhaji-Trajkovic L, Kravic-Stevovic T, et al. The protective role of AMP-activated protein kinase in alpha-synuclein neurotoxicity in vitro. Neurobiol Dis. 2014; 63:1-11. doi: 10.1016/j.nbd.2013.11.002 PMID: 24269733
93. Seo JH, Rah JC, Choi S.H., Shin JK, Min K, Kim HS, et al Alpha-synuclein regulates neuronal survival via Bcl-2 family expression and PI3/Akt kinase pathway. FASEBJ. 2002; 16:1826-1828. PMID: 12223445
94. Volpicelli-Daley L.A., Luk KC, Patel TP, Tanik SA, Riddle DM, Stieber A, et al. Exogenous osynuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron. 2011; 72:57-71. doi: 10.1016/j.neuron.2011.08.033 PMID: 21982369
95. Hamza TH, Chen H, Hill-Burns EM, Rhodes SL, Montimurro J, Kay DM, et al. Genome-wide gene-environment study identifies glutamate receptor gene GRIN2Aas a Parkinson's disease modifier gene via interaction with coffee. PLoS Genet. 2011; 7:e1002237. doi: 10.1371/journal.pgen.1002237 PMID: 21876681
96. Johnston T, Duty S. GABA(B) receptor agonists reverse akinesia following intranigral or intracerebro-ventricular injection in the reserpine-treated rat. Br J Pharmacol. 2003; 139:1480-1486. PMID: 12922935